



# International Journal of Reproductive Medicine & Gynecology

Short Communication

## Pelvic Lymphadenectomy-an Essential Part of Surgical Treatment of Cervical Cancer - ৩

Sabera Khatun\*

*Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka, Bangladesh*

**\*Address for Correspondence:** Sabera Khatun, Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka, Bangladesh, Tel: + 008801819216254; E-mail: sabera120khatun12@yahoo.com

**Submitted:** 29 August 2017; **Approved:** 02 October 2017; **Published:** 05 October 2017

**Cite this article:** Khatun S. Pelvic Lymphadenectomy-an Essential Part of Surgical Treatment of Cervical Cancer. Int J Reprod Med Gynecol. 2017;3(2): 040-042.

**Copyright:** © 2017 Khatun S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In Bangladesh, the incidence of cervical cancer is about 13,000 and around 6600 women dies from cervical cancer each year [1]. Cervical cancer constitutes 22-29% of the female cancer in Bangladesh [2,3]. Diagnosis and treatment of CIN through population-based screening programs has lead to 50-80% reduction in deaths from cervical cancer in various developed countries [4].

Cervical cancer is a slowly progressing tumour and its natural history is reasonably well understood. The cancer starts as a preinvasive form, known as Cervical Intraepithelial Neoplasia (CIN). It is graded as CIN I, II and III. Only 2-3% of CIN I and 33-34% of CIN II and III progress to invasive cancer. This total process may take 10 to 15 years. If, during this slow progression period, CIN can be diagnosed and treated, development of invasive cervical cancer can be prevented. It is now widely accepted that detection and treatment of CIN can reduce the incidence of cervical cancer by population-based organized cervical cancer screening program and there is significant reduction in the incidence of cervical cancer in screened population in developed countries.

Invasive cervical cancer starts from stage IA<sub>1</sub> through to stage IV B. All the stages are- IA<sub>1</sub>, IA<sub>2</sub>, IB<sub>1</sub>, IB<sub>2</sub>, IIA<sub>1</sub>, IIA<sub>2</sub>, IIB, IIIA, IIIB, IVA and IVB. Surgical treatment can only be implemented upto stage IIA<sub>2</sub>. But only stage IB<sub>1</sub> and IIA<sub>1</sub> are universally treated by radical hysterectomy and Bilateral Pelvic Lymphadenectomy (BLPND).

There are five types of hysterectomies which can be applied for the treatment of cervical cancer.

Type I or extrafascial hysterectomy done for stage IA<sub>1</sub> disease.

Type II or modified radical hysterectomy or Wertheim's hysterectomy done for stage IA<sub>2</sub> disease.

Type III or radical hysterectomy done for stage IB<sub>1</sub> and stage IIA<sub>1</sub> disease.

Type IV or extended radical hysterectomy done for selective small central recurrence after radiotherapy.

Type V or pelvic exenteration done for central recurrences with involvement of the lower most part of the ureter and the bladder.

First three types of hysterectomies are always associated with bilateral pelvic lymph node dissection because pelvic lymph nodes are the commonest and first site of metastasis from cervical cancer. The rate of involvement of the pelvic lymph nodes in different stages is as follows:

Stage IA <sub>1</sub>	-	0.5%
Stage IA <sub>2</sub>	-	5-13%
Stage IB <sub>1-2</sub>	-	17.3%
Stage IIA-B	-	30%
Stage IIIA-B	-	45%

(Jonathan S. Berek)

In Bangladesh, it is the most common gynaecological cancer and the most important cause of cancer related death in female. Here, 70% patients of cervical cancer come for treatment in inoperable stage. Only 30% can be treated by primary surgery. Bilateral pelvic lymphadenectomy is an essential part of primary radical surgery for cervical cancer. The status of the regional lymph nodes is one of the most important prognostic factor for cervical cancer [5-7].

The benefits of lymphadenectomy may extend beyond merely detecting metastatic disease. Survival benefit has also been noted among node negative patients who undergo more extensive lymphadenectomy [8-16]. To date, relatively little data exist to describe the possible benefits of a more extensive lymphadenectomy for early stage cervical cancer. Study of histopathological reports of the specimen of radical hysterectomy and Bilateral Pelvic Lymphadenectomy (BLPND) can contribute a lot to take the decision for adjuvant therapy for operable cases.

In Bangabandhu Sheikh Mujib Medical University (BSMMU) of Dhaka, Bangladesh, a retrospective analysis of histopathological reports of lymph nodes removed of 105 cases was done. Among them, 20 patients had lymph nodes positive for malignancy. Among all the factors, only age of the patients were found to be positively related with lymph node metastasis (p value < 0.001). Other factors like histological type of tumour, number of nodes removed stage and parity of the patients were not positively related with lymph node metastasis.

In conclusion, our findings suggest that the extent of lymphadenectomy performed for patients with early stage cervical cancer influence the outcome. Best results are observed in node negative patients, provided the greater number of nodes removed. Further work is required to determine the survival advantage with the number of nodes removed.

## REFERENCES

1. Bray F, Pisani P, Parkin DM. GLOBOCON 2002. Cancer incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 version 2.0. Lyon: IARC Press; 2004.
2. Akhter PS, Uddin MM, Sharma SK. Patterns of malignant neoplasia-analysis of 1020 cases in three years. J of Teachers' Association, SBMCH, Bangladesh. 1996; 7: 439-445.
3. Akhter PS, Uddin MM, Akhter N. Gynaecological cancers—analysis of 1020 cases in three years. Journal of Teachers' Association, Sher-e-Bangla Medical College Hospital. Bangladesh. 1996; 439-445.
4. International Agency for Research on Cancer. IARC Handbooks on Cancer Prevention. Volume 10. Cervix Cancer Screening. IARC Press: Lyon.2004; <https://goo.gl/YYHi4C>
5. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecological Oncology Group study. Gynecol Oncol. 1990; 38: 352-357. <https://goo.gl/5qqYga>
6. Tanaka Y, Sawada S, Murata T. Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol Oncol. 1984; 23: 455-459. <https://goo.gl/qQBvZL>
7. Tinga DJ, Timmer PR, Bouma J, Aalders JG. Prognostic significance of single versus multiple lymph node metastases in cervical carcinoma stage IB. Gynecol Oncol. 1990; 39: 175-180. <https://goo.gl/WsGJhc>
8. Chan AD, Essner R, Wanek LA, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg. 2000; 191: 16-22. <https://goo.gl/t91YbD>
9. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007; 99: 433-441. <https://goo.gl/beaeAn>
10. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005; 23: 3668-3675. <https://goo.gl/aEHjyN>
11. Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol. 2003; 21: 1029-1034. <https://goo.gl/DN3gaV>

12. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. *Gynecol Oncol.* 1995; 56: 29-33. <https://goo.gl/QDn3VN>
13. Krag DN, Single RM. Breast cancer survival according to number of nodes removed. *Ann Surg Oncol.* 2003; 10: 1152-1159. <https://goo.gl/uEcyAi>
14. Sosa JA, Diener-West M, Gusev Y, Choti MA, Lange JR, Dooley WC, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. *Ann Surg Oncol.* 1998; 5: 140-149. <https://goo.gl/pb7d3X>
15. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. *J Clin Oncol.* 2001; 19: 157-163. <https://goo.gl/qVLMPz>
16. Weir L, Speers C, D'yachkova Y, Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. *J Clin Oncol.* 2002; 20: 1793-1799. <https://goo.gl/qHcSa4>